A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell Transplantation
Study of VOR33 in Patients with Acute Myeloid Leukemia (AML)
Sponsor: Vor Biopharma
Enrolling: Male and Female Patients
IRB Number: AAAU4826
U.S. Govt. ID: NCT04849910
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: You are being asked to take part in this study because you have acute myeloid leukemia (AML). Vor Biopharma, is a company that is testing a possible new treatment for AML. This possible new treatment, is VOR33. In this study, your blood-forming stem cells will be genetically modified to become VOR33. VOR33 has not been approved by the Food and Drug Administration (FDA). This is a first time VOR33 is being studied in humans. The sponsor of this study is looking to find out if VOR33 is safe.
Markus Mapara, MD
Do You Qualify?
Are you between the ages of 18-70? Yes No
Have you been diagnosed with Acute Myeloid Leukemia (AML)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator